Additionally, MTX has demonstrated efficacy when paired with anti-tumor necrosis factor-alpha (TNF-α) drugs in the treatment of individuals suffering from ulcerative colitis, breast cancer, lung carcinoma, head and neck malignancies, and ovarian carcinoma (Chande et al. 2014). This evidence concerns the gene TNF and ovarian carcinoma.